Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
240.65
+3.30 (1.39%)
At close: Mar 6, 2026, 4:00 PM EST
236.01
-4.64 (-1.93%)
After-hours: Mar 6, 2026, 5:35 PM EST
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 15 analysts that cover Ascendis Pharma stock have a consensus rating of "Strong Buy" and an average price target of $278.8, which forecasts a 15.85% increase in the stock price over the next year. The lowest target is $250 and the highest is $342.
Price Target: $278.8 (+15.85%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 6 | 6 | 5 |
| Buy | 10 | 9 | 9 | 10 | 10 | 10 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 15 | 15 | 16 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $250 → $275 | Buy | Maintains | $250 → $275 | +14.27% | Mar 3, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $246 → $262 | Buy | Maintains | $246 → $262 | +8.87% | Feb 12, 2026 |
| Wedbush | Wedbush | Buy Maintains $240 → $273 | Buy | Maintains | $240 → $273 | +13.44% | Feb 12, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $246 → $260 | Strong Buy | Maintains | $246 → $260 | +8.04% | Jan 30, 2026 |
| Barclays | Barclays | Buy Initiates $342 | Buy | Initiates | $342 | +42.12% | Jan 28, 2026 |
Financial Forecast
Revenue This Year
1.43B
from 720.13M
Increased by 98.02%
Revenue Next Year
2.04B
from 1.43B
Increased by 43.13%
EPS This Year
4.80
from -3.76
EPS Next Year
11.05
from 4.80
Increased by 130.30%
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.6B | 2.5B | |||
| Avg | 1.4B | 2.0B | |||
| Low | 1.2B | 1.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 122.6% | 74.4% | |||
| Avg | 98.0% | 43.1% | |||
| Low | 62.7% | 13.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 8.73 | 18.44 | |||
| Avg | 4.80 | 11.05 | |||
| Low | 1.84 | 4.84 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 284.1% | |||
| Avg | - | 130.3% | |||
| Low | - | 0.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.